There is a growing trend towards downsizing of the internal discovery at big pharma. Most of the major pharmaceutical and biotech companies are considering outsourcing as a core strategy for developing their discovery pipelines.  Nowadays, focused and cost-efficient Contract Research Organisations (CRO) offer greater flexibility and diversity for pharma R&D efforts.

Bienta is a trademark for preclinical biology services department of Enamine, the world’s largest supplier of novel drug-like molecules for drug discovery research located in Kyiv, Ukraine. Bienta is operating as a CRO providing high-throughput pharmacological screening and comprehensive bioanalytical support of drug discovery projects, including in vitro ADMET (absorption, distribution, metabolism, excretion, toxicity)  testing, pharmacokinetics, as well as toxicity and efficacy studies in animals. Tight integration with the world-class organic chemistry powerhouse allows Bienta to provide seamless and cost-efficient support throughout drug discovery and early development stages – starting with novel molecules and assay development and ending with validated, optimized drug candidates.